Trending...
- A 40-Year Secret Finally Finds Its Voice: Aketous Releases Retro-Pop Anthem "Touch My Soul"
- When Interpretation Becomes Conversation: Rethinking Engagement in the Museum Age
- Roshni Online Services Unveils Plans for Innovative Digital Consultation Platform
Caring Brands Inc. (N A S D A Q: CABR) $CABR Has Revenues From Enzyme Booster for Hair Loss, and Photocil for Psoriasis and Vitiligo via Sales in the US and Licensees in India
FORT PIERCE, Fla. - eMusicWire -- Marketing a Portfolio of Unique, Patented and Clinically Validated Products for Skin and Hair Growth.
Plans to Launch 5 Products Over the Next 2 Years in Addition to In-Licensing Additional Products.
Management has a Successful Track Record of Strategic Acquisitions, Rapid Product Development, IP Development and Product Licensing.
Revenues From Sales of Hair Enzyme Booster for Hair Loss, and Photocil for Psoriasis and Vitiligo via Sales in the US and Licensees in India.
Additional Product Opportunities Include Treatment of Eczema and a Sunscreen That Prevents Jellyfish Stings.
Two New U.S. Patents Strengthening Hair Enzyme Booster Technology.
Exclusive Global License with Itonis, Inc. to Manufacture and Market Emesyl Over-The-Counter Nausea Relief Product.
Agreement Includes Royalty Structure Based on Future Net Sales Plus Potential for CABR to Earn Equity in Itonis, Inc. Tied to Revenue Milestones.
Global Market for Nausea Treatment and Related Therapies Projected to Exceed $6.23 Billion USD.
$4 Million Public Offering Completed with Uplisting to N A S D A Q.
Caring Brands Inc. (N A S D A Q: CABR) has a growing portfolio of unique, patented, and clinically validated products for skin and hair growth. CABR intends to launch a total of 5 products over the next 2 years in addition to in-licensing additional products. CABR management has a successful track record of strategic acquisitions, rapid product development, IP development and product licensing. Revenues from the sales of Hair Enzyme Booster for the treatment of hair loss, and Photocil for the treatment of psoriasis and vitiligo, are currently being generated by direct sales in the US and licensees in India. Additional product opportunities include CB-101 for the treatment of eczema, NoStingz, a sunscreen that prevents jellyfish stings.
More on eMusic Wire
Two New U.S. Patents Strengthening Hair Enzyme Booster Technology
On February 3rd CABR announced the issuance of two new United States patents covering proprietary methods and compositions designed to enhance enzymatic activity in hair follicles, further strengthening the Company's intellectual property portfolio supporting its Hair Enzyme Booster product.
The newly issued CABR patents, granted by the United States Patent and Trademark Office in January 2026, relate to technologies that increase sulfotransferase enzyme activity to improve the efficacy of topical hair loss treatments. These patents expand the CABR exclusive protection around mechanisms that are central to the Hair Enzyme Booster, which is currently generating revenue through direct sales in the United States and via international licensees. The newly granted patents support CABR ability to commercialize enzyme-based solutions that may improve treatment responsiveness in a broader patient population.
Exclusive Global License with Itonis to Manufacture and Market Emesyl OTC Nausea Relief Product
On January 5th CABR announced that it has entered into an exclusive worldwide license agreement with Itonis Inc. to manufacture, market, and distribute Emesyl, Itonis's over-the-counter (OTC) nausea relief product. The agreement provides CABR with full rights to commercialize Emesyl and to oversee all manufacturing activities associated with the product.
CABR will assume responsibility for product manufacturing, marketing, sales strategy, and global distribution. Itonis will provide technical information, product formulation data, historical sales information, and intellectual property details to support the CABR commercial launch and ongoing development efforts.
According to QY Research, the global market for nausea treatment and related therapies is projected to exceed USD 6.23 billion in 2025, underscoring the broader commercial context for the Emesyl license.
More on eMusic Wire
The agreement includes a royalty structure based on future net sales, along with the potential for CABR to earn equity in Itonis tied to revenue milestones. CABR expects to provide further updates on product timelines, manufacturing progress, and commercial rollout as these initiatives advance.
Glynn Wilson, CEO CABR, said, "Securing the exclusive rights to Emesyl marks an important milestone for Caring Brands as we expand our health and wellness portfolio. Emesyl brings a recognized product with real commercial potential, and we look forward to revitalizing and scaling its market presence. This agreement aligns perfectly with our long‑term strategy for OTC products, and we are excited to share more about our upcoming plans in the months ahead."
CABR Closing of $4,000,000 Million Uplisting to N A S D A Q
On November 14th CABR announced the closing of its underwritten U.S. public offering of 1,000,000 shares of common stock at a public offering price of $4.00 per share for aggregate gross proceeds of approximately US $4,000,000, prior to deducting underwriting discounts and offering expenses. The shares of common stock commenced trading on the Nasdaq Capital Markets on November 13, 2025.
In addition, CABR granted the underwriter a 45-day option to purchase up to an additional 150,000 shares at the public offering price, less the underwriting discounts and commissions.
CABR intends to use the net proceeds received from this offering for general and working capital purposes, including but not limited to marketing and sales of its proprietary products, and for the repayment of certain debt. D. Boral Capital LLC acted as the sole underwriter in connection with this offering.
For more information on CABR visit: www.caringbrands.com
Media Contact
Company Name: Caring Brands Inc. (N A S D A Q: CABR)
Contact: Brian S John, Chief Investment Officer
Email: info@caringbrands.com
Phone: (561) 896-7616
Country: United States
Website: www.caringbrands.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Plans to Launch 5 Products Over the Next 2 Years in Addition to In-Licensing Additional Products.
Management has a Successful Track Record of Strategic Acquisitions, Rapid Product Development, IP Development and Product Licensing.
Revenues From Sales of Hair Enzyme Booster for Hair Loss, and Photocil for Psoriasis and Vitiligo via Sales in the US and Licensees in India.
Additional Product Opportunities Include Treatment of Eczema and a Sunscreen That Prevents Jellyfish Stings.
Two New U.S. Patents Strengthening Hair Enzyme Booster Technology.
Exclusive Global License with Itonis, Inc. to Manufacture and Market Emesyl Over-The-Counter Nausea Relief Product.
Agreement Includes Royalty Structure Based on Future Net Sales Plus Potential for CABR to Earn Equity in Itonis, Inc. Tied to Revenue Milestones.
Global Market for Nausea Treatment and Related Therapies Projected to Exceed $6.23 Billion USD.
$4 Million Public Offering Completed with Uplisting to N A S D A Q.
Caring Brands Inc. (N A S D A Q: CABR) has a growing portfolio of unique, patented, and clinically validated products for skin and hair growth. CABR intends to launch a total of 5 products over the next 2 years in addition to in-licensing additional products. CABR management has a successful track record of strategic acquisitions, rapid product development, IP development and product licensing. Revenues from the sales of Hair Enzyme Booster for the treatment of hair loss, and Photocil for the treatment of psoriasis and vitiligo, are currently being generated by direct sales in the US and licensees in India. Additional product opportunities include CB-101 for the treatment of eczema, NoStingz, a sunscreen that prevents jellyfish stings.
More on eMusic Wire
- Hoy Law Wins Supreme Court Decision Establishing Federal Trucking Regulations as the Standard of Care in South Dakota
- Dr. Rashad Richey's Indisputable Shatters Records, Over 1 Billion YouTube Views, Top 1% Podcast, 3.2 Million Viewers Daily
- Grand Opening: New Single-Family Homes Now Open for Sale at Heritage at Manalapan
- Shelter Structures America Announces Distribution Partnership with The DuraTrac Group
- The OpenSSL Corporation Releases Its Annual Report 2025
Two New U.S. Patents Strengthening Hair Enzyme Booster Technology
On February 3rd CABR announced the issuance of two new United States patents covering proprietary methods and compositions designed to enhance enzymatic activity in hair follicles, further strengthening the Company's intellectual property portfolio supporting its Hair Enzyme Booster product.
The newly issued CABR patents, granted by the United States Patent and Trademark Office in January 2026, relate to technologies that increase sulfotransferase enzyme activity to improve the efficacy of topical hair loss treatments. These patents expand the CABR exclusive protection around mechanisms that are central to the Hair Enzyme Booster, which is currently generating revenue through direct sales in the United States and via international licensees. The newly granted patents support CABR ability to commercialize enzyme-based solutions that may improve treatment responsiveness in a broader patient population.
Exclusive Global License with Itonis to Manufacture and Market Emesyl OTC Nausea Relief Product
On January 5th CABR announced that it has entered into an exclusive worldwide license agreement with Itonis Inc. to manufacture, market, and distribute Emesyl, Itonis's over-the-counter (OTC) nausea relief product. The agreement provides CABR with full rights to commercialize Emesyl and to oversee all manufacturing activities associated with the product.
CABR will assume responsibility for product manufacturing, marketing, sales strategy, and global distribution. Itonis will provide technical information, product formulation data, historical sales information, and intellectual property details to support the CABR commercial launch and ongoing development efforts.
According to QY Research, the global market for nausea treatment and related therapies is projected to exceed USD 6.23 billion in 2025, underscoring the broader commercial context for the Emesyl license.
More on eMusic Wire
- Iranian-Born Engineer Mohsen Bahmani Introduces Propeller-Less Propulsion for Urban Air Mobility
- Aleen Inc. (C S E: ALEN.U) Advances Digital Wellness Vision with Streamlined Platform Navigation and Long-Term Growth Strategy
- RimbaMindaAI Officially Launches Version 3.0 Following Strategic Breakthrough in Malaysian Market Analysis
- Fed Rate Pause & Dow 50k: Irfan Zuyrel on Liquidity Shifts, Crypto Volatility, and the ASEAN Opportunity
- 20/20 Institute Launches Updated Vision Correction Procedures Page for Denver & Colorado Springs
The agreement includes a royalty structure based on future net sales, along with the potential for CABR to earn equity in Itonis tied to revenue milestones. CABR expects to provide further updates on product timelines, manufacturing progress, and commercial rollout as these initiatives advance.
Glynn Wilson, CEO CABR, said, "Securing the exclusive rights to Emesyl marks an important milestone for Caring Brands as we expand our health and wellness portfolio. Emesyl brings a recognized product with real commercial potential, and we look forward to revitalizing and scaling its market presence. This agreement aligns perfectly with our long‑term strategy for OTC products, and we are excited to share more about our upcoming plans in the months ahead."
CABR Closing of $4,000,000 Million Uplisting to N A S D A Q
On November 14th CABR announced the closing of its underwritten U.S. public offering of 1,000,000 shares of common stock at a public offering price of $4.00 per share for aggregate gross proceeds of approximately US $4,000,000, prior to deducting underwriting discounts and offering expenses. The shares of common stock commenced trading on the Nasdaq Capital Markets on November 13, 2025.
In addition, CABR granted the underwriter a 45-day option to purchase up to an additional 150,000 shares at the public offering price, less the underwriting discounts and commissions.
CABR intends to use the net proceeds received from this offering for general and working capital purposes, including but not limited to marketing and sales of its proprietary products, and for the repayment of certain debt. D. Boral Capital LLC acted as the sole underwriter in connection with this offering.
For more information on CABR visit: www.caringbrands.com
Media Contact
Company Name: Caring Brands Inc. (N A S D A Q: CABR)
Contact: Brian S John, Chief Investment Officer
Email: info@caringbrands.com
Phone: (561) 896-7616
Country: United States
Website: www.caringbrands.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: CorporateAds
0 Comments
Latest on eMusic Wire
- CCHR: Taxpayer Billions Wasted on Mental Health Research as Outcomes Deteriorate
- Digital Efficiency Consulting Group (DECG) Officially Launches
- Work 365 Delivers Purpose-Built Revenue Operations for Microsoft Cloud for US Government
- Meridianvale Unveils QarvioFin Public Beta: The First 'Glass Box' AI Operating System for Autonomous Finance
- Milap announce Spring 2026 Programme showcasing some of the finest UK Indo-Jazz
- The Hedgehogs Release Debut Album The Hedgehogs/Winter, Available Now
- Mend Colorado Launches Revamped Sports Performance Training Page
- Parkway Prosthodontics Achieves Breakthrough Full-Arch Reconstruction Case
- Postmortem Pathology Expands to Phoenix: Bringing Families Answers During Their Most Difficult Moments
- Blasting Off with Space Sector Companies: Artemis II Manned Moon Mission is Set to Launch: Could $ASTI be on the Same Rocket Ride as $ASTS & $LUNR?
- Costa Oil Named Primary Sponsor of Carson Ware for the United Rentals 300 at Daytona International Speedway
- HBMHCW Expande Infraestructura de Cumplimiento para Argentina mientras América Latina Supera $1.5 Billones en Volumen Cripto
- Norisia Launches AI Formulated Luxury Multivitamin to Transform Daily Wellness in the UK
- i'N'i release EP title track single 'SUPANATURAL'
- Marcos Luis, Beloved Host @ OneMicNite, Announces Jermaine Jones (American Idol) as S7 Opening Guest
- FPFX Tech & PropAccount.com Partner with Investing Expos to Advance the Global Prop Trading Industry
- Jude & Frank Joins Lohrasp Kansara on a Sophisticated Afro-House Take on a Brazilian Classic
- Jacob Emrani's Annual "Supper Bowl" Expected To Donate Thousands Of Meals
- NASA / Glenn Research Center Collaboration to Help Meet Rising Demand for Space Energy Beaming Tech / CIGS PV Modules from Ascent Solar: NAS DAQ: ASTI
- When Interpretation Becomes Conversation: Rethinking Engagement in the Museum Age